BAY 1217389 is primarily investigated for its potential in cancer therapy, particularly as a targeted treatment for various malignancies. It functions as a potent inhibitor of specific kinases involved in tumor growth and survival pathways. By blocking these kinases, it aims to disrupt the proliferation of cancer cells and induce apoptosis. Its application is currently focused on preclinical and clinical studies to evaluate its efficacy and safety in treating solid tumors and hematologic cancers. Researchers are also exploring its potential in combination therapies to enhance treatment outcomes and overcome drug resistance in advanced cancers.